Curated News
By: NewsRamp Editorial Staff
June 22, 2026

Onco-Innovations Hits 99.3% Purity in Drug Scale-Up, Appoints New CFO

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Onco-Innovations advances PNKP inhibitor program with 99.3% pure API batch, strengthening its oncology drug pipeline.
  • Dalton Pharma Services produced a 300-gram batch of A83B4C63 with 99.3% purity and no residual solvents for Onco-Innovations.
  • Onco-Innovations' scalable manufacturing of ONC010 brings potential cancer treatments closer to clinical trials and patients.
  • Onco-Innovations appoints Dave Antony as CFO to lead financial strategy alongside its drug manufacturing milestone.

Impact - Why it Matters

This milestone is significant because it demonstrates that Onco-Innovations' ONC010 drug candidate can be manufactured at scale with high purity and consistency, a critical step toward clinical trials and eventual commercialization. For investors and patients, it signals progress in developing a potential new treatment for solid tumours, addressing a major unmet need in oncology. The appointment of a new CFO also strengthens the company's financial leadership as it moves toward First-in-Human studies.

Summary

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) has achieved a critical manufacturing milestone with the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient supporting its proprietary ONC010 drug candidate. The batch, produced as part of Dalton Pharma Services’ Process Optimization and Intermediate Scale-Up Program, attained approximately 99.3% purity with no detectable residual solvents after rigorous quality control and Certificate of Analysis review. This milestone underscores the reproducibility and scalability of the manufacturing process, which is expected to support future analytical qualification, formulation development, engineering batch production, and GMP manufacturing activities ahead of planned First-in-Human studies.

In addition to this manufacturing achievement, Onco-Innovations announced the appointment of Dave Antony as chief financial officer and corporate secretary, effective immediately, succeeding Nico Mah. Antony brings extensive financial expertise to the company as it advances its PNKP inhibitor program. Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions, and it has secured an exclusive worldwide license to patented technology targeting solid tumours.

The news was disseminated via BioMedWire, a specialized communications platform within IBN's Dynamic Brand Portfolio, which focuses on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. For more details, the full press release can be accessed at https://ibn.fm/NJVb1. Investors seeking the latest news and updates regarding ONNVF can find them in the company’s newsroom at https://ibn.fm/ONNVF.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations Hits 99.3% Purity in Drug Scale-Up, Appoints New CFO

blockchain registration record for this content.